Alphamab Oncology is an investment holding company. The company is headquartered in Suzhou, Jiangsu and currently employs 484 full-time employees. The company went IPO on 2019-12-12. The Company’s in-house pipeline consists of antibody-drug conjugates (ADCs), monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s product pipeline includes KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), JSKN016(HER3/TROP2 bispecific antibody ADC), JSKN033(subcutaneous co-formulation of JSKN003 and KN035), used for indications such as 1L sq NSCLC, 1L HER2+ BC, 1L biliary track cancer, advanced solid tumors, HER2-expressing solid tumors and others.
09966.HK stock price ended at $10.2 on 星期五, after dropping 0.78%
On the latest trading day Jan 16, 2026, the stock price of 09966.HK fell by 0.78%, dropping from $10.28 to $10.20. During the session, the stock saw a volatility of 5.37%, with prices oscillating between a daily low of $9.87 and a high of $10.40. On the latest trading day, the trading volume for 09966.HK rose by 575.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 1.4M shares were traded, with a market value of approximately $9.8B.